<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30267" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Topiramate</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fariba</surname>
            <given-names>Kamron A.</given-names>
          </name>
          <aff>University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadabadi</surname>
            <given-names>Abdolreza</given-names>
          </name>
          <aff>Western University/ Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kamron Fariba declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>6</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30267.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">This&#x000a0;activity provides a detailed overview of topiramate, a second-generation antiepileptic drug approved by the FDA in 1996. Topiramate is indicated for the management of epilepsy and migraines and is also approved for chronic weight management in individuals with a body mass index&#x000a0;greater than&#x000a0;30 kg/m<sup>2</sup>. This discussion&#x000a0;focuses on the pharmacology of topiramate, including its mechanism of action, dosing guidelines, pharmacokinetics, significant drug interactions, clinical toxicology, and monitoring requirements. Additionally, this session covers adverse events associated with topiramate, highlighting key considerations for interprofessional teams involved in the care of patients with epilepsy, migraine, and related conditions.</p>
        <p>This activity aims to enhance healthcare professionals' capabilities in prescribing and managing topiramate therapy effectively by examining off-label uses and the latest clinical evidence. The goal is to equip participants with the knowledge necessary to implement optimal treatment plans and adjust dosages to minimize adverse effects while maximizing therapeutic benefits. This will support healthcare professionals in making well-informed decisions in their clinical practice, thereby improving patient outcomes&#x000a0;while managing epilepsy, migraine, and weight management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Evaluate&#x000a0;the mechanism of action of topiramate.</p></list-item><list-item><p>Identify the indications of topiramate.</p></list-item><list-item><p>Determine the recommended clinical monitoring for patients&#x000a0;receiving&#x000a0;topiramate.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from topiramate treatment.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30267&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30267">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30267.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Topiramate is an antiepileptic drug (AED), a group of medications primarily indicated for treating seizure disorders, reflecting their designation as "antiepileptic." These drugs are also traditionally used as mood stabilizers in psychiatry, with expanding applications over time.<xref ref-type="bibr" rid="article-30267.r1">[1]</xref> Topiramate, specifically, is an anticonvulsant that received FDA approval in 1996 for use as monotherapy and adjunctive therapy in epilepsy, as well as for treating migraine disorders.<xref ref-type="bibr" rid="article-30267.r2">[2]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Topiramate is approved&#x000a0;as monotherapy&#x000a0;for epilepsy for individuals aged&#x000a0;2 years and older with primary generalized onset tonic-clonic or partial-onset seizures.<xref ref-type="bibr" rid="article-30267.r3">[3]</xref> Additionally, it is sanctioned for adjunctive therapy in adults and pediatric populations from ages 2 to 16 years with primary generalized onset tonic-clonic seizures, partial-onset seizures, and for those aged&#x000a0;2 years or older with seizures associated with Lennox-Gastaut syndrome.<xref ref-type="bibr" rid="article-30267.r4">[4]</xref><xref ref-type="bibr" rid="article-30267.r5">[5]</xref>&#x000a0;Topiramate is approved for migraine prevention in adults. Furthermore, it is approved for chronic weight management in individuals with a body mass index over 30 kg/m<sup>2</sup> and as part of a fixed-dose combination with phentermine for obesity management.<xref ref-type="bibr" rid="article-30267.r6">[6]</xref><xref ref-type="bibr" rid="article-30267.r7">[7]</xref><xref ref-type="bibr" rid="article-30267.r8">[8]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Topiramate has numerous off-label applications, including the treatment of neuropathic pain, psychotropic drug-induced weight gain, alcohol and tobacco dependence, prevention of cluster headaches, binge eating disorder, bulimia nervosa, and obesity with hypertension.&#x000a0;Topiramate is also used in preventing neuralgiform attacks, adjunctive therapy in bipolar disorder, and managing unipolar depression, borderline personality disorder, obsessive-compulsive disorder, posttraumatic stress disorder, Tourette syndrome, Prader-Willi syndrome, and essential tremor.<xref ref-type="bibr" rid="article-30267.r9">[9]</xref><xref ref-type="bibr" rid="article-30267.r10">[10]</xref>&#x000a0;Topiramate has shown efficacy in treating alcohol use disorder in individuals unresponsive to naltrexone/acamprosate and is considered as effective and safe as naltrexone for reducing heavy alcohol consumption, irrespective of genetic polymorphisms.<xref ref-type="bibr" rid="article-30267.r11">[11]</xref> Additionally, topiramate is utilized for binge eating disorders.<xref ref-type="bibr" rid="article-30267.r12">[12]</xref><xref ref-type="bibr" rid="article-30267.r13">[13]</xref> An emerging drug-device combination using the SipNose intranasal delivery platform, which facilitates direct nose-to-brain transport, is being developed for binge eating disorder treatment. However, it has not yet received FDA approval.<xref ref-type="bibr" rid="article-30267.r14">[14]</xref></p>
      </sec>
      <sec id="article-30267.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Although topiramate's precise mechanism of action remains unclear, sufficient evidence explains its anticonvulsant activity.<xref ref-type="bibr" rid="article-30267.r15">[15]</xref><xref ref-type="bibr" rid="article-30267.r16">[16]</xref> Topiramate blocks voltage-gated sodium channels, likely leading to sustained depolarization control during seizures.<xref ref-type="bibr" rid="article-30267.r17">[17]</xref>&#x000a0;Topiramate reduces membrane depolarization via AMPA/Kainate receptors and enhances GABA-A receptor activity, strengthening inhibitory effects.<xref ref-type="bibr" rid="article-30267.r6">[6]</xref> Additionally, topiramate acts as a weak carbonic anhydrase inhibitor; acidosis in the brain partially protects against seizures by downregulating NMDA receptor activity. Overall, the influence of topiramate on these channels is the primary explanation for its antiepileptic effects.<xref ref-type="bibr" rid="article-30267.r18">[18]</xref><xref ref-type="bibr" rid="article-30267.r19">[19]</xref> The efficacy of topiramate in migraine is likely due to inhibitory effects on AMPA and kainate subtypes of glutamate receptors and, to a lesser extent, voltage-gated calcium channels. Calcitonin gene-related peptide (CGRP) has emerged as a therapeutic target for migraine. Topiramate inhibits the release of CGRP and glutamate from trigeminal neurovascular nerve endings, effectively disrupting cortical spreading depression and demonstrating efficacy in managing both epilepsy and migraine.<xref ref-type="bibr" rid="article-30267.r20">[20]</xref> In individuals with frequent episodic migraines, topiramate may prevent the transition to chronic migraine.<xref ref-type="bibr" rid="article-30267.r21">[21]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Topiramate is well absorbed from the gastrointestinal tract, with peak plasma levels typically achieved in 2 to 3 hours. The bioavailability exceeds 80%. Concomitant ingestion of food delays the time to reach peak plasma concentration but does not significantly alter the extent of absorption. Thus, topiramate can be administered without regard to meals.&#x000a0;Topiramate follows linear and predictable pharmacokinetics over the recommended dose range (15 to 400 mg/d).</p>
        <p><bold>Distribution:</bold> Topiramate&#x000a0;displays plasma protein binding&#x000a0;ranging from 15% to 41%. The fraction of bound topiramate decreases as blood concentration increases.</p>
        <p><bold>Metabolism:</bold> Topiramate undergoes metabolism through hydroxylation, hydrolysis, and glucuronidation.</p>
        <p><bold>Excretion:</bold> Topiramate is eliminated primarily through renal excretion, both unchanged and as metabolites. Clearance in adults is 20 to 30 mL/min. The mean plasma elimination half-life is approximately 21 hours, varying with age and the concomitant use of enzyme-inducing or inhibiting drugs. Clearance increases in patients taking concomitant enzyme-inducing drugs such as phenytoin, barbiturates, and carbamazepine.<xref ref-type="bibr" rid="article-30267.r22">[22]</xref></p>
      </sec>
      <sec id="article-30267.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Topiramate is available for both adult and pediatric populations in&#x000a0;2 oral preparations: immediate-release (taken twice daily) and extended-release (taken once daily). Patients should not crush the tablets due to their bitter taste. There is also a sprinkle capsule formulation that may be added to a small amount of soft food; administration of topiramate may occur without regard to meals. The oral solution is available at a concentration of 25 mg/mL. Alcohol should be avoided for 6 hours before and after administering topiramate.<xref ref-type="bibr" rid="article-30267.r22">[22]</xref> Importantly, some extended-release formulations of topiramate are not bioequivalent.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p><bold>Monotherapy for partial-onset seizures and primary generalized tonic-clonic seizures:</bold> The suggested dose for topiramate in adults and pediatric patients 10 years and older is 400 mg/d in&#x000a0;2 divided doses. A slow titration schedule of 25 to 50 mg/d in weekly increments is preferred to decrease the frequency of adverse effects.<xref ref-type="bibr" rid="article-30267.r23">[23]</xref></p>
        <p><bold>Adjunctive therapy for primary generalized tonic-clonic seizures, partial-onset seizures, or Lennox-Gastaut Syndrome:</bold> The suggested total daily dose of topiramate as an adjunctive treatment in adults with partial onset seizures is 200 to 400 mg/d in&#x000a0;2 divided doses for primary generalized tonic-clonic seizures. Treatment should be initiated at a lower dose (25 to 50 mg/d) followed by an up-titration of 25 to 50 mg/d weekly.<xref ref-type="bibr" rid="article-30267.r24">[24]</xref><xref ref-type="bibr" rid="article-30267.r25">[25]</xref></p>
        <p><bold>Migraine prevention:</bold> According to guidelines from the American Academy of Neurology, topiramate is an effective therapy for migraine prevention (level A), significantly decreasing the frequency and severity of migraine attacks. The recommended dose range is 25 to 50 mg. Patients with a favorable response to topiramate pharmacotherapy within 4 to 8 weeks should continue treatment for at least&#x000a0;6 months to achieve maximum benefit. Dose escalation up to 200 mg may be required in selected patients.<xref ref-type="bibr" rid="article-30267.r26">[26]</xref> According to consensus from the American Academy of Neurology and American Headache Society, children and adolescents receiving topiramate experience a decrease in headache days and migraine attacks.<xref ref-type="bibr" rid="article-30267.r27">[27]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> Topiramate plasma concentrations may be increased in patients with hepatic impairment. However, the increase is not significant, and no dose adjustment is generally suggested.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;Half the standard dose is recommended for moderate to severe renal impairment and ESRD. As topiramate is removed by dialysis, a supplemental dose may be required during hemodialysis.<xref ref-type="bibr" rid="article-30267.r28">[28]</xref></p>
        <p><bold>Pregnancy considerations:</bold> A topiramate dose of less than 200 mg daily does not affect the pharmacokinetic levels of oral contraceptive pills containing 35 &#x003bc;g of ethinyl estradiol. The dose of topiramate used for migraine prevention (25 to 50 mg) is not supposed to reduce contraceptive efficacy.<xref ref-type="bibr" rid="article-30267.r29">[29]</xref> According to clinical data from the NAAED pregnancy registry, there may be an increased risk of oral cleft (1.4%) when infants are exposed to topiramate. First-trimester exposure to topiramate monotherapy is associated with an increased frequency of cleft lip with or without cleft palate and small for gestational age. A study indicates an increased risk of autism spectrum disorders and intellectual disability due to prenatal exposure to topiramate.<xref ref-type="bibr" rid="article-30267.r30">[30]</xref> Topiramate should be considered in pregnancy only after a comprehensive risk-benefit evaluation.<xref ref-type="bibr" rid="article-30267.r26">[26]</xref></p>
        <p><bold>Breastfeeding considerations:</bold> Maternal doses of topiramate up to 200 mg daily produce a low concentration in infant serum. Sedation and diarrhea have been reported in breastfed infants, but most infants tolerate the drug in milk well. The infant should be monitored for diarrhea, drowsiness, irritability, weight gain, and developmental milestones. Caution is required in exclusively breastfed infants and simultaneous use of antiepileptics or psychotropic drugs.<xref ref-type="bibr" rid="article-30267.r31">[31]</xref></p>
        <p><bold>Pediatric patients:</bold> The meta-analysis aimed to evaluate the efficacy and safety of topiramate in pediatric migraine. Topiramate was associated with higher rates of adverse drug reactions such as weight loss and paresthesia. Topiramate is effective in reducing the number of monthly headache days in patients under the age of 18 who experience migraines, thus alleviating the burden of migraine-related symptoms.<xref ref-type="bibr" rid="article-30267.r32">[32]</xref> Oligohidrosis, hyperthermia, and reduction in bone mineral density have been reported in pediatric patients.</p>
        <p><bold>Older patients:</bold> Dosage adjustment of topiramate may be required for patients with creatinine clearance &#x0003c;70 mL/min/1.73 m<sup>2</sup>.</p>
      </sec>
      <sec id="article-30267.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects are dose-dependent and vary between&#x000a0;patients with epilepsy and migraine, as the trials use different doses based on the condition.<xref ref-type="bibr" rid="article-30267.r22">[22]</xref></p>
        <p>The most common adverse effects in epilepsy trials included central nervous system involvement (paresthesia, fatigue, cognitive problems, dizziness, somnolence, psychomotor slowing, memory/concentration difficulties, nervousness, confusion), endocrine/metabolism issues (weight loss, anorexia), respiratory problems (infection), and miscellaneous effects (fever, flushing).<xref ref-type="bibr" rid="article-30267.r33">[33]</xref><xref ref-type="bibr" rid="article-30267.r34">[34]</xref>&#x000a0;In trials involving patients with migraine, the most common adverse effects are paresthesia and dysgeusia.<xref ref-type="bibr" rid="article-30267.r35">[35]</xref></p>
        <p>Severe adverse drug reactions include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute myopia and secondary angle-closure glaucoma&#x000a0;<xref ref-type="bibr" rid="article-30267.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p>Oligohidrosis and hyperthermia (uncommon, reversible with cessation of the drug)&#x000a0;<xref ref-type="bibr" rid="article-30267.r37">[37]</xref></p>
          </list-item>
          <list-item>
            <p>Metabolic acidosis: Due to inhibition of carbonic anhydrase isoenzymes, topiramate can lead to metabolic acidosis secondary to type II renal tubular acidosis, elevated urine pH, reduced urine citrate, hypercalciuria, calcium phosphate stone formation, bone mineralization defects.<xref ref-type="bibr" rid="article-30267.r38">[38]</xref></p>
          </list-item>
          <list-item>
            <p>Suicidal behavior and ideation&#x000a0;<xref ref-type="bibr" rid="article-30267.r39">[39]</xref></p>
          </list-item>
          <list-item>
            <p>Cognitive/neuropsychiatric adverse reactions: The influence of topiramate on the hippocampus-related memory processes influences spatial memory but does not significantly affect the learning process.<xref ref-type="bibr" rid="article-30267.r40">[40]</xref></p>
          </list-item>
          <list-item>
            <p>Fetal toxicity: Exposure during pregnancy is associated with congenital malformations and developmental delay. Increased risk of recurrent malformations in future pregnancies.<xref ref-type="bibr" rid="article-30267.r41">[41]</xref></p>
          </list-item>
          <list-item>
            <p>Hyperammonemia and encephalopathy: One case report describes a young patient developing metabolic encephalopathy with hypoxic respiratory failure, most likely due to concurrent use of valproic acid and topiramate. Clinicians should be cautious of possible hyperammonemia encephalopathy in patients taking these medications presenting with impaired consciousness and cognitive decline.<xref ref-type="bibr" rid="article-30267.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Kidney stones: Long-term topiramate administration could induce urolithiasis; therefore, blood testing for acid-base balance, urinary pH, and citrate is recommended in patients with kidney stones.<xref ref-type="bibr" rid="article-30267.r42">[42]</xref></p>
          </list-item>
          <list-item>
            <p>Paresthesia is the most common cause of discontinuation.<xref ref-type="bibr" rid="article-30267.r43">[43]</xref></p>
          </list-item>
          <list-item>
            <p>Adjustment of dose in renal failure: Dose adjustment is necessary for patients with moderate-to-severe renal impairment.<xref ref-type="bibr" rid="article-30267.r44">[44]</xref></p>
          </list-item>
          <list-item>
            <p>Hepatotoxicity: A literature review indicates that&#x000a0;&#x0003c;1% of subjects have&#x000a0;increased&#x000a0;serum aminotransferase levels during long-term topiramate therapy. The hepatotoxicity is&#x000a0;believed&#x000a0;to be due to a toxic intermediate formation. Cases with lactic acidosis and hyperammonemia may be caused by mitochondrial dysfunction.<xref ref-type="bibr" rid="article-30267.r45">[45]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Concurrent use of topiramate and metformin increases the risk of metabolic acidosis. Simultaneous use is contraindicated.<xref ref-type="bibr" rid="article-30267.r46">[46]</xref></p>
          </list-item>
          <list-item>
            <p>Topiramate increases the oral clearance of high-dose estrogen contraceptives and can lead to contraception failure (&#x0003e;200 mg/d).<xref ref-type="bibr" rid="article-30267.r47">[47]</xref></p>
          </list-item>
          <list-item>
            <p>Clearance of topiramate may be reduced when used with amitriptyline. Use with caution.<xref ref-type="bibr" rid="article-30267.r47">[47]</xref></p>
          </list-item>
          <list-item>
            <p>Concurrent administration of topiramate with carbamazepine requires dose adjustments due to reduced topiramate concentrations.<xref ref-type="bibr" rid="article-30267.r48">[48]</xref></p>
          </list-item>
          <list-item>
            <p>Concurrent use of carbonic anhydrase inhibitors like acetazolamide, dorzolamide, and brinzolamide with topiramate may increase the risk of&#x000a0;metabolic acidosis and nephrolithiasis. Avoid co-administration.<xref ref-type="bibr" rid="article-30267.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>Concurrent use of topiramate with benzodiazepines, alcohol, thalidomide, and bromperidol can cause sedation and excessive CNS depression.</p>
          </list-item>
          <list-item>
            <p>An increase in systemic exposure to lithium may occur with&#x000a0;high doses of topiramate (600 mg/d). Therefore, it is advisable to monitor lithium levels when co-administering high-dose topiramate.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30267.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Topiramate is a relatively safe drug,&#x000a0;and the list of absolute contraindications is minimal. As a carbonic anhydrase inhibitor, topiramate can precipitate the development of metabolic acidosis and is, therefore, contraindicated in individuals currently with (or prone to) metabolic acidosis. Other contraindications include those with a history of a proven allergy to topiramate or individuals who have consumed (or will consume) alcohol within 6 hours.<xref ref-type="bibr" rid="article-30267.r26">[26]</xref></p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p><bold>Acute myopia and secondary angle-closure glaucoma:</bold> Ophthalmologic findings associated with topiramate may include myopia, increased intraocular pressure, ocular hyperemia, macular striae, choroidal detachment, anterior chamber shallowing, mydriasis, and retinal pigment epithelial detachment. Supraciliary effusion can precipitate anterior displacement of the lens and iris, leading to secondary angle-closure glaucoma. Symptoms typically emerge within one month of initiating topiramate. Unlike primary narrow-angle glaucoma, secondary-angle closure glaucoma induced by topiramate can occur in pediatric and adult populations. Discontinuation of topiramate may be required.<xref ref-type="bibr" rid="article-30267.r36">[36]</xref> Drug-induced choroidal effusion syndrome should be considered as a possible cause of bilateral acute angle-closure glaucoma in patients with myopia and a shallow anterior chamber.<xref ref-type="bibr" rid="article-30267.r49">[49]</xref></p>
        <p><bold>Negative effects on growth:</bold> According to product labeling, topiramate can reduce body weight in pediatric populations. Additionally, a reduction in height velocity and height change has been noted with topiramate use. Adverse effects on weight and height are evident across all age subgroups of topiramate users. Therefore, careful growth monitoring is essential in children receiving prolonged topiramate treatment.</p>
        <p>Other warnings related to topiramate use are covered in adverse drug reactions.</p>
      </sec>
      <sec id="article-30267.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Baseline and periodic serum bicarbonate levels are required for individuals on topiramate due to concerns about metabolic acidosis. Healthcare professionals should also monitor renal function tests. The American Epilepsy Society states that antiepileptic drug-level testing, including for topiramate, is not routinely necessary when seizures are controlled without adverse effects. However, monitoring topiramate levels is advisable in special cases, such as weight-based dose adjustments for young children, assessing patient adherence, managing polypharmacy, and detecting suspected toxicity. Due to variability in topiramate plasma concentration with concomitant antiepileptic drug use, monitoring plasma concentration may be beneficial for optimizing drug dosage.<xref ref-type="bibr" rid="article-30267.r19">[19]</xref><xref ref-type="bibr" rid="article-30267.r50">[50]</xref>&#x000a0;Healthcare professionals should also obtain serum prolactin levels to differentiate between psychogenic nonepileptic seizures (PNES) and generalized tonic-clonic or complex partial seizures.<xref ref-type="bibr" rid="article-30267.r51">[51]</xref></p>
        <p>Healthcare professionals should monitor for a reduction in the frequency of the most debilitating seizures, such as drop attacks and tonic-clonic seizures when using topiramate for Lennox-Gastaut syndrome (LGS).<xref ref-type="bibr" rid="article-30267.r25">[25]</xref></p>
        <p>They should also monitor for a reduction in the frequency and severity of headaches. A decrease in the frequency of migraine days is a key measure of the efficacy of migraine prevention.<xref ref-type="bibr" rid="article-30267.r52">[52]</xref>&#x000a0;A network meta-analysis&#x000a0;reported that topiramate increases the proportion of patients achieving a reduction of 50% or more in monthly migraine days compared to those receiving a placebo.<xref ref-type="bibr" rid="article-30267.r53">[53]</xref></p>
      </sec>
      <sec id="article-30267.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Symptoms of toxicity include sedation, speech disturbances, blurred vision, agitation, ataxia, convulsions, and abdominal pain. Arterial blood gas analysis in a topiramate overdose usually shows hyperchloremic normal anion gap metabolic acidosis.<xref ref-type="bibr" rid="article-30267.r54">[54]</xref></p>
        <p>In&#x000a0;7 cases of topiramate toxicity observed by Poison Control Centers in Poland, somnolence&#x000a0;was the most common symptom (66.7%), along with agitation, mydriasis, and vertigo (33.4%). One individual experienced&#x000a0;3 tonic-clonic seizures. There&#x000a0;were no fatalities or long-term consequences.<xref ref-type="bibr" rid="article-30267.r55">[55]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Currently, no specific antidote is available. If symptoms are refractory to ongoing treatment, hemodialysis can reduce topiramate concentrations.<xref ref-type="bibr" rid="article-30267.r28">[28]</xref>&#x000a0;A recent case report involved a 32-year-old woman who presented following the intentional ingestion of 36 g of topiramate. Following hemodialysis, significant neurological improvement occurred, including the resolution of encephalopathic features and cessation of myoclonic jerking. Gas chromatography/mass spectrometry showed a marked reduction in topiramate levels, underscoring the effectiveness of hemodialysis in managing severe topiramate toxicity by facilitating rapid clearance of the drug.<xref ref-type="bibr" rid="article-30267.r56">[56]</xref></p>
      </sec>
      <sec id="article-30267.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Topiramate is FDA-approved for various types of epilepsy, migraine, and Lennox-Gastaut syndrome; however, it has numerous off-label uses and a significant adverse drug reaction profile. Therefore, healthcare professionals must continually educate themselves on the most up-to-date information regarding new medical information. Clinicians prescribe topiramate for specific indications. Neurologist and epileptologist consultations are required for refractory seizures and seizures associated with Lennox-Gastaut syndrome. For various off-label uses, consultation with other specialties may be essential. Nurses monitor for any adverse events and patient compliance. Pharmacists are crucial in verifying medication reconciliation and reporting significant interactions to the prescriber.</p>
        <p>The brand name of topiramate may be confused with the brand name of a commonly used extended-release &#x003b2;-blocker. Consequently, pharmacists must be careful while dispensing the drug.<xref ref-type="bibr" rid="article-30267.r57">[57]</xref> Emergency medicine physicians and nurses rapidly stabilize the patient in an overdose. Critical care physicians and medical toxicologists are crucial in managing patients with massive overdoses. Once the patient is stable, a psychiatric evaluation and support are necessary. Interprofessional coordination between clinicians (MDs, DOs, NPs, PAs), nurses, pharmacists, specialists, and other healthcare workers is essential to decrease adverse events and improve patient outcomes related to topiramate therapy.</p>
      </sec>
      <sec id="article-30267.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30267&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30267">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30267/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30267">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30267.s11">
        <title>References</title>
        <ref id="article-30267.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lieb</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>V&#x000f6;llm</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>R&#x000fc;cker</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Timmer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stoffers</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials.</article-title>
            <source>Br J Psychiatry</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>196</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-12</page-range>
            <pub-id pub-id-type="pmid">20044651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Gadde</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Weight Loss Medications in the Treatment of Obesity and Hypertension.</article-title>
            <source>Curr Hypertens Rep</source>
            <year>2019</year>
            <month>Feb</month>
            <day>12</day>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>16</fpage>
            <pub-id pub-id-type="pmid">30747357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kazerooni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Topiramate-Associated Weight Loss in a Veteran Population.</article-title>
            <source>Mil Med</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>181</volume>
            <issue>3</issue>
            <fpage>283</fpage>
            <page-range>283-6</page-range>
            <pub-id pub-id-type="pmid">26926755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raru</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zeid</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Hypoxic respiratory failure due to hyperammonemic encephalopathy induced by concurrent use of valproic acid and topiramate, a case report and review of the literature.</article-title>
            <source>Respir Med Case Rep</source>
            <year>2018</year>
            <volume>25</volume>
            <fpage>1</fpage>
            <page-range>1-3</page-range>
            <pub-id pub-id-type="pmid">29872630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bosanac</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rossell</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Treating OCD: what to do when first-line therapies fail.</article-title>
            <source>Australas Psychiatry</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>350</fpage>
            <page-range>350-3</page-range>
            <pub-id pub-id-type="pmid">26104775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Minton</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Bookstaver</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Love</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Topiramate: safety and efficacy of its use in the prevention and treatment of migraine.</article-title>
            <source>J Cent Nerv Syst Dis</source>
            <year>2011</year>
            <volume>3</volume>
            <fpage>155</fpage>
            <page-range>155-68</page-range>
            <pub-id pub-id-type="pmid">23861645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Babaei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Geller</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Vidmar</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>A Narrative Review: Phentermine and Topiramate for the Treatment of Pediatric Obesity.</article-title>
            <source>Adolesc Health Med Ther</source>
            <year>2023</year>
            <volume>14</volume>
            <fpage>125</fpage>
            <page-range>125-140</page-range>
            <pub-id pub-id-type="pmid">37641650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trinkley</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Phentermine/topiramate for the treatment of obesity.</article-title>
            <source>Ann Pharmacother</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>47</volume>
            <issue>3</issue>
            <fpage>340</fpage>
            <page-range>340-9</page-range>
            <pub-id pub-id-type="pmid">23482732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnone</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Review of the use of Topiramate for treatment of psychiatric disorders.</article-title>
            <source>Ann Gen Psychiatry</source>
            <year>2005</year>
            <month>Feb</month>
            <day>16</day>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <pub-id pub-id-type="pmid">15845141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soyka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy of alcoholism - an update on approved and off-label medications.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>12</issue>
            <fpage>1187</fpage>
            <page-range>1187-1199</page-range>
            <pub-id pub-id-type="pmid">28658981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morley</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Kranzler</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Luquin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jamshidi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Montebello</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tremonti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dali</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Logge</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Baillie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Teesson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trent</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Haber</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.</article-title>
            <source>Am J Psychiatry</source>
            <year>2024</year>
            <month>May</month>
            <day>01</day>
            <volume>181</volume>
            <issue>5</issue>
            <fpage>403</fpage>
            <page-range>403-411</page-range>
            <pub-id pub-id-type="pmid">38706338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McElroy</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Capece</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Beyers</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>NR</given-names>
              </name>
              <collab>Topiramate Binge Eating Disorder Research Group</collab>
            </person-group>
            <article-title>Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study.</article-title>
            <source>Biol Psychiatry</source>
            <year>2007</year>
            <month>May</month>
            <day>01</day>
            <volume>61</volume>
            <issue>9</issue>
            <fpage>1039</fpage>
            <page-range>1039-48</page-range>
            <pub-id pub-id-type="pmid">17258690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Himmerich</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>YD</given-names>
              </name>
              <name>
                <surname>Conti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mutwalli</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Karwautz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sj&#x000f6;gren</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Uribe Isaza</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Tyszkiewicz-Nwafor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aigner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McElroy</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Treasure</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>S</given-names>
              </name>
              <collab>WFSBP Task Force on Eating Disorders</collab>
            </person-group>
            <article-title>World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders.</article-title>
            <source>World J Biol Psychiatry</source>
            <year>2023</year>
            <month>Apr</month>
            <day>24</day>
            <fpage>1</fpage>
            <page-range>1-64</page-range>
            <pub-id pub-id-type="pmid">37350265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kobo-Greenhut</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zohar-Beja</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hadar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Itzhaki</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Karasik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caraco</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Frankenthal</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shahaf</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ekstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shichor</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gur</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>SipNose-topiramate: a potential novel approach to binge eating management.</article-title>
            <source>J Eat Disord</source>
            <year>2023</year>
            <month>Jun</month>
            <day>26</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>102</fpage>
            <pub-id pub-id-type="pmid">37365668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parikh</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Current Status of Antiepileptic Drugs as Preventive Migraine Therapy.</article-title>
            <source>Curr Treat Options Neurol</source>
            <year>2019</year>
            <month>Mar</month>
            <day>18</day>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>16</fpage>
            <pub-id pub-id-type="pmid">30880369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Supuran</surname>
                <given-names>CT</given-names>
              </name>
            </person-group>
            <article-title>Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2016</year>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>423</fpage>
            <page-range>423-31</page-range>
            <pub-id pub-id-type="pmid">26878088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lauritzen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dreier</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Fabricius</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hartings</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Graf</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Strong</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical relevance of cortical spreading depression in neurological disorders: migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury.</article-title>
            <source>J Cereb Blood Flow Metab</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-35</page-range>
            <pub-id pub-id-type="pmid">21045864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vega</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Maalouf</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Sakhaee</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Increased propensity for calcium phosphate kidney stones with topiramate use.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>547</fpage>
            <page-range>547-57</page-range>
            <pub-id pub-id-type="pmid">17877442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Contin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Riva</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Albani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Avoni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baruzzi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.</article-title>
            <source>Ther Drug Monit</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>332</fpage>
            <page-range>332-7</page-range>
            <pub-id pub-id-type="pmid">12021622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Advances in topiramate as prophylactic treatment for migraine.</article-title>
            <source>Brain Behav</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>10</issue>
            <fpage>e2290</fpage>
            <pub-id pub-id-type="pmid">34472696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kowacs</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Sampaio Rocha-Filho</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Peres</surname>
                <given-names>MFP</given-names>
              </name>
              <name>
                <surname>Edvinsson</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The history and rationale of the development of new drugs for migraine treatment.</article-title>
            <source>Arq Neuropsiquiatr</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>81</volume>
            <issue>12</issue>
            <fpage>1084</fpage>
            <page-range>1084-1097</page-range>
            <pub-id pub-id-type="pmid">38157876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khalil</surname>
                <given-names>NY</given-names>
              </name>
              <name>
                <surname>AlRabiah</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Al Rashoud</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Bari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wani</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Topiramate: Comprehensive profile.</article-title>
            <source>Profiles Drug Subst Excip Relat Methodol</source>
            <year>2019</year>
            <volume>44</volume>
            <fpage>333</fpage>
            <page-range>333-378</page-range>
            <pub-id pub-id-type="pmid">31029222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alfaris</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Minnick</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hopkins</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Berkowitz</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Wadden</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Combination phentermine and topiramate extended release in the management of obesity.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>8</issue>
            <fpage>1263</fpage>
            <page-range>1263-74</page-range>
            <pub-id pub-id-type="pmid">25958964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coppola</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Caliendo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Veggiotti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Romeo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tortorella</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Marco</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pascotto</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Topiramate as add-on drug in children, adolescents and young adults with Lennox-Gastaut syndrome: an Italian multicentric study.</article-title>
            <source>Epilepsy Res</source>
            <year>2002</year>
            <month>Sep</month>
            <volume>51</volume>
            <issue>1-2</issue>
            <fpage>147</fpage>
            <page-range>147-53</page-range>
            <pub-id pub-id-type="pmid">12350390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asadi-Pooya</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Lennox-Gastaut syndrome: a comprehensive review.</article-title>
            <source>Neurol Sci</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>403</fpage>
            <page-range>403-414</page-range>
            <pub-id pub-id-type="pmid">29124439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Topiramate in Migraine Prevention: A 2016 Perspective.</article-title>
            <source>Headache</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>165</fpage>
            <page-range>165-178</page-range>
            <pub-id pub-id-type="pmid">27902848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oskoui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pringsheim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Billinghurst</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Potrebic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gersz</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Gloss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Holler-Managan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Leininger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Licking</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Powers</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Sowell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Victorio</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Yonker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zanitsch</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hershey</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.</article-title>
            <source>Neurology</source>
            <year>2019</year>
            <month>Sep</month>
            <day>10</day>
            <volume>93</volume>
            <issue>11</issue>
            <fpage>500</fpage>
            <page-range>500-509</page-range>
            <pub-id pub-id-type="pmid">31413170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manitpisitkul</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Curtin</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Shalayda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Heald</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment.</article-title>
            <source>Epilepsy Res</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>108</volume>
            <issue>5</issue>
            <fpage>891</fpage>
            <page-range>891-901</page-range>
            <pub-id pub-id-type="pmid">24725807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <article-title>Gynecologic Management of Adolescents and Young Women With Seizure Disorders: ACOG Committee Opinion, Number 806.</article-title>
            <source>Obstet Gynecol</source>
            <year>2020</year>
            <month>May</month>
            <volume>135</volume>
            <issue>5</issue>
            <fpage>e213</fpage>
            <page-range>e213-e220</page-range>
            <pub-id pub-id-type="pmid">32332416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bj&#x000f8;rk</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Zoega</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Leinonen</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Dreier</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Furu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gilhus</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Gissler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>H&#x000e1;lfd&#x000e1;narson</surname>
                <given-names>&#x000d3;</given-names>
              </name>
              <name>
                <surname>Igland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tomson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Alvestad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability.</article-title>
            <source>JAMA Neurol</source>
            <year>2022</year>
            <month>Jul</month>
            <day>01</day>
            <volume>79</volume>
            <issue>7</issue>
            <fpage>672</fpage>
            <page-range>672-681</page-range>
            <pub-id pub-id-type="pmid">35639399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r31">
          <label>31</label>
          <element-citation publication-type="book">
            <chapter-title>Topiramate</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>11</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">30000318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Shan</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The Efficacy and Safety of Topiramate in the Prevention of Pediatric Migraine: An Update Meta-Analysis.</article-title>
            <source>Front Pediatr</source>
            <year>2020</year>
            <volume>8</volume>
            <fpage>28</fpage>
            <pub-id pub-id-type="pmid">32175291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Novotny</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Renfroe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yardi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nordli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ness</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kurland</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Yuen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Eerdekens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Venkatraman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nye</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures.</article-title>
            <source>Neurology</source>
            <year>2010</year>
            <month>Mar</month>
            <day>02</day>
            <volume>74</volume>
            <issue>9</issue>
            <fpage>714</fpage>
            <page-range>714-20</page-range>
            <pub-id pub-id-type="pmid">20089937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanner</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ashman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gloss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Harden</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bourgeois</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bautista</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Abou-Khalil</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Burakgazi-Dalkilic</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Llanas Park</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hirtz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nespeca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gidal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Faught</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.</article-title>
            <source>Neurology</source>
            <year>2018</year>
            <month>Jul</month>
            <day>10</day>
            <volume>91</volume>
            <issue>2</issue>
            <fpage>74</fpage>
            <page-range>74-81</page-range>
            <pub-id pub-id-type="pmid">29898971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pulman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jette</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dykeman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hemming</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hutton</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Marson</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Topiramate add-on for drug-resistant partial epilepsy.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>Feb</month>
            <day>25</day>
            <issue>2</issue>
            <fpage>CD001417</fpage>
            <pub-id pub-id-type="pmid">24570033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sierra-Rodr&#x000ed;guez</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Vicente</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chavarri-Garc&#x000ed;a</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Del R&#x000ed;o-Mayor</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Acute narrow-angle glaucoma induced by topiramate with acute myopia and macular striae: A case report.</article-title>
            <source>Arch Soc Esp Oftalmol (Engl Ed)</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>94</volume>
            <issue>3</issue>
            <fpage>130</fpage>
            <page-range>130-133</page-range>
            <pub-id pub-id-type="pmid">30591244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karachristianou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Papamichalis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sarantopoulos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boura</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Georgiadis</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Hypohidrosis induced by topiramate in an adult patient.</article-title>
            <source>Epileptic Disord</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>203</fpage>
            <page-range>203-6</page-range>
            <pub-id pub-id-type="pmid">23773932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Emmett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fenves</surname>
                <given-names>AZ</given-names>
              </name>
            </person-group>
            <article-title>Topiramate and metabolic acidosis: an evolving story.</article-title>
            <source>Hosp Pract (1995)</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>5</issue>
            <fpage>192</fpage>
            <page-range>192-195</page-range>
            <pub-id pub-id-type="pmid">28828886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abraham</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Topiramate-induced suicidality.</article-title>
            <source>Can J Psychiatry</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>127</fpage>
            <page-range>127-8</page-range>
            <pub-id pub-id-type="pmid">12655915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pietrzak</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Konopka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wojcieszak</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Effect of topiramate on hippocampus-dependent spatial memory in rats.</article-title>
            <source>Pharmacol Rep</source>
            <year>2013</year>
            <volume>65</volume>
            <issue>5</issue>
            <fpage>1152</fpage>
            <page-range>1152-62</page-range>
            <pub-id pub-id-type="pmid">24399711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campbell</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Devenney</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smithson</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Parsons</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Irwin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero.</article-title>
            <source>Epilepsia</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>165</fpage>
            <page-range>165-71</page-range>
            <pub-id pub-id-type="pmid">23167802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salek</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Andel</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kurfurstova</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Topiramate induced metabolic acidosis and kidney stones - a case study.</article-title>
            <source>Biochem Med (Zagreb)</source>
            <year>2017</year>
            <month>Jun</month>
            <day>15</day>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>404</fpage>
            <page-range>404-410</page-range>
            <pub-id pub-id-type="pmid">28694730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Golpayegani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gharagozli</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Newer Antiepileptic Drugs Discontinuation due to Adverse Effects: An Observational Study.</article-title>
            <source>Ann Indian Acad Neurol</source>
            <year>2019</year>
            <season>Jan-Mar</season>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-30</page-range>
            <pub-id pub-id-type="pmid">30692756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamamoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Usui</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nishida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Imai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kagawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Influence of Renal Function on Pharmacokinetics of Antiepileptic Drugs Metabolized by CYP3A4 in a Patient With Renal Impairment.</article-title>
            <source>Ther Drug Monit</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>144</fpage>
            <page-range>144-147</page-range>
            <pub-id pub-id-type="pmid">29095797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r45">
          <label>45</label>
          <element-citation publication-type="book">
            <chapter-title>Topiramate</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>7</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">31643944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salpeter</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Greyber</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pasternak</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Salpeter</surname>
                <given-names>EE</given-names>
              </name>
            </person-group>
            <article-title>Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2010</year>
            <month>Apr</month>
            <day>14</day>
            <volume>2010</volume>
            <issue>4</issue>
            <fpage>CD002967</fpage>
            <pub-id pub-id-type="pmid">20393934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bialer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Doose</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Murthy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Curtin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Twyman</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Schwabe</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic interactions of topiramate.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2004</year>
            <volume>43</volume>
            <issue>12</issue>
            <fpage>763</fpage>
            <page-range>763-80</page-range>
            <pub-id pub-id-type="pmid">15355124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mack</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Kuc</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mulcrone</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Pilley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;newald</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Interaction of topiramate with carbamazepine: two case reports and a review of clinical experience.</article-title>
            <source>Seizure</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>7</issue>
            <fpage>464</fpage>
            <page-range>464-7</page-range>
            <pub-id pub-id-type="pmid">12237076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lobo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lobo</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Topiramate-induced ocular complications: case series.</article-title>
            <source>Rom J Ophthalmol</source>
            <year>2024</year>
            <season>Jan-Mar</season>
            <volume>68</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-74</page-range>
            <pub-id pub-id-type="pmid">38617722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bourgeois</surname>
                <given-names>BF</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and metabolism of topiramate.</article-title>
            <source>Drugs Today (Barc)</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-8</page-range>
            <pub-id pub-id-type="pmid">12973408</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>So</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>RS</given-names>
              </name>
              <collab>Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology</collab>
            </person-group>
            <article-title>Use of serum prolactin in diagnosing epileptic seizures: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.</article-title>
            <source>Neurology</source>
            <year>2005</year>
            <month>Sep</month>
            <day>13</day>
            <volume>65</volume>
            <issue>5</issue>
            <fpage>668</fpage>
            <page-range>668-75</page-range>
            <pub-id pub-id-type="pmid">16157897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Tanna</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hatswell</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Sapra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Villa</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Migraine day frequency in migraine prevention: longitudinal modelling approaches.</article-title>
            <source>BMC Med Res Methodol</source>
            <year>2019</year>
            <month>Jan</month>
            <day>23</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <pub-id pub-id-type="pmid">30674285</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lampl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>MaassenVanDenBrink</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Deligianni</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Gil-Gouveia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jassal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sanchez-Del-Rio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reuter</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Uluduz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Versijpt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zeraatkar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sacco</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis.</article-title>
            <source>J Headache Pain</source>
            <year>2023</year>
            <month>May</month>
            <day>19</day>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>56</fpage>
            <pub-id pub-id-type="pmid">37208596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mirza</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Marson</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Pirmohamed</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effect of topiramate on acid-base balance: extent, mechanism and effects.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>68</volume>
            <issue>5</issue>
            <fpage>655</fpage>
            <page-range>655-61</page-range>
            <pub-id pub-id-type="pmid">19916989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wi&#x0015b;niewski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x00141;ukasik-G&#x00142;ebocka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anand</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Acute topiramate overdose--clinical manifestations.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>317</fpage>
            <page-range>317-20</page-range>
            <pub-id pub-id-type="pmid">19514879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <article-title>2023 ACMT Annual Scientific Meeting Abstracts - San Diego, CA.</article-title>
            <source>J Med Toxicol</source>
            <year>2023</year>
            <month>Mar</month>
            <day>23</day>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>63</fpage>
            <page-range>63-168</page-range>
            <pub-id pub-id-type="pmid">36952114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30267.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Salazar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amato</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Volk</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Schiff</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Using drug knowledgebase information to distinguish between look-alike-sound-alike drugs.</article-title>
            <source>J Am Med Inform Assoc</source>
            <year>2018</year>
            <month>Jul</month>
            <day>01</day>
            <volume>25</volume>
            <issue>7</issue>
            <fpage>872</fpage>
            <page-range>872-884</page-range>
            <pub-id pub-id-type="pmid">29800453</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
